Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oxford BioMedica ( (GB:OXB) ) just unveiled an update.
Oxford Biomedica has rejected a series of takeover proposals from private equity group EQT, which has now formally ruled out making an offer for the company under UK takeover rules. The board, having consulted key shareholders, unanimously concluded that four successive proposals, including possible cash offers and an unlisted share alternative, significantly undervalued the group and its prospects.
With EQT now constrained by Rule 2.8 of the Takeover Code, Oxford Biomedica’s board is doubling down on its standalone strategy in viral vector contract manufacturing. The company points to strong demand, a robust pipeline and scalable capabilities as the basis for continued progress towards its financial objectives, reinforcing its ambition to cement a leading position in the cell and gene therapy CDMO market and create long-term value for shareholders.
The most recent analyst rating on (GB:OXB) stock is a Hold with a £904.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
The score is primarily held back by weak financial performance—ongoing losses, negative cash flows, and high leverage—despite strong recent revenue growth. Technicals are supportive due to a strong uptrend and positive MACD, but very overbought RSI/Stoch readings add near-term downside risk. Valuation is constrained by negative earnings and the absence of a dividend yield.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
Oxford Biomedica is a UK-headquartered, FTSE 250-listed contract development and manufacturing organisation specialising in cell and gene therapy. The company focuses on viral vector technologies, including lentiviral, AAV and adenoviral systems, offering end-to-end development and manufacturing services to global pharmaceutical and biotech clients from early-stage development through commercialisation.
Average Trading Volume: 314,915
Technical Sentiment Signal: Buy
Current Market Cap: £825.3M
For a thorough assessment of OXB stock, go to TipRanks’ Stock Analysis page.